Research Papers:

Stability and anti-tumor effect of oncolytic herpes simplex virus type 2

Yang Wang, Jing Jin, Zhen Wu, Sheng Hu, Han Hu, Zhifeng Ning, Yanfei Li, Yuting Dong, Jianwen Zou, Zeyong Mao, Xiaotai Shi, Huajun Zheng, Shuang Dong, Fuxing Liu, Zhizheng Fang, Jiliang Wu and Binlei Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:24672-24683. https://doi.org/10.18632/oncotarget.25122

Metrics: PDF 768 views  |   HTML 1381 views  |   ?  


Yang Wang1,*, Jing Jin1,*, Zhen Wu1,*, Sheng Hu2,*, Han Hu1, Zhifeng Ning3, Yanfei Li4, Yuting Dong5, Jianwen Zou4, Zeyong Mao5, Xiaotai Shi5, Huajun Zheng6, Shuang Dong2, Fuxing Liu3, Zhizheng Fang5, Jiliang Wu7 and Binlei Liu1,4

1National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, Hubei Key Laboratory of Industrial Microbiology, Hubei University of Technology, Wuhan, 430068, Hubei, China

2Department of Medical Oncology, Hubei Cancer Hospital, Wuhan, 430079, Hubei, China

3Basic Medicine College, Hubei University of Science and Technology, Xianning, 437100, Hubei, China

4College of Pharmacology, Hubei University of Science and Technology, Xianning, 437100, Hubei, China

5Wuhan Binhui Biotechnology Co., Ltd., Wuhan, 430075, Hubei, China

6Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, 201203, Shanghai, China

7Hubei Provincial Key Laboratory of Cardiocerebrovascular and Metabolic Diseases, Hubei University of Science and Technology, Xianning, 437100, Hubei, China

*These authors have contributed equally to this work

Correspondence to:

Binlei Liu, email: 1836035949@qq.com

Jiliang Wu, email: xywjl@163.com

Keywords: herpes simplex virus type 2; stability; anti-tumor effect

Received: August 24, 2017     Accepted: March 22, 2018     Published: May 15, 2018


Oncolytic virotherapy is a new therapeutic strategy based on the inherent cytotoxicity of viruses and their ability to replicate and spread in tumors in a selective manner. We constructed a new type of oncolytic herpes simplex virus type 2 (oHSV-2, named OH2) to treat human cancers, but a systematic evaluation of the stability and oncolytic ability of this virus is lacking. In this study, we evaluated its physical stability, gene modification stability and biological characteristics stability, including its anti-tumor activity in an animal model. The physical characteristics as well as genetic deletions and insertions in OH2 were stable, and the anti-tumor activity remained stable even after passage of the virus for more than 20 generations. In conclusion, OH2 is a virus that has stable structural and biological traits. Furthermore, OH2 is a potent oncolytic agent against tumor cells.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25122